21200 ⎘
Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant; Organic adjuvants Saponins; Quil A; QS21; ISCOMS
Oil-based adjuvants
#302IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF
#303COMPOSITION
#304COMPOSITIONS
#305Canine babesiosis vaccine antigen
#306HENDRA AND NIPAH VIRUS G GLYCOPROTEIN IMMUNOGENIC COMPOSITIONS
#307Vaccines against clostridium difficile comprising recombinant toxins
#308ANTI-TUMOR COMPOSITIONS AND USES THEREOF
#309Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
#310QUIL A FRACTION WITH LOW TOXICITY AND USE THEREOF
#311Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
#312VACCINE
#313Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
#314Compositions and methods
#315Spray dried compositions and methods of use
#316Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
#317Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
#318Compositions and methods for detecting microbial infections
#319Conditional replicating cytomegalovirus as a vaccine for CMV
#320Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
#321Method of inducing a proinflammatory immune response to human α-lactalbumin
#322Composition comprising iscom particles and live micro-organisms
#323Recombinant HCV E2 glycoprotein
#324Vaccine
#325Compositions for canine respiratory disease complex
#326Adjuvant compositions
#327Method for preventing or treating infection
#328Polyvalent conjugate vaccine for cancer
#329Reassortant BTV and AHSV vaccines
#330Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
#331Compositions and methods
#332Schmallenberg virus (SBV) vaccine, methods of production, and uses thereof
#333Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region
#334antigenic composition
#335compositions and methods thereof
#336Heterologous prime boost vaccination regimen against malaria
#337Recombinant subunit dengue virus vaccine
#338Rotavirus subunit vaccines and methods of making and use thereof
#339Immunotherapeutic method involving CD123 (IL-3Rα) antibodies and immunostimulating complex
#340Viral particles derived from an enveloped virus
#341Influenza vaccine
#342Vaccines comprising cholesterol and CpG as sole adjuvant-carrier molecules
#343Parasite vaccine
#344Prevention And Treatment Of Amyloidogenic Disease
#345RECOMBINANT MULTIMERIC INFLUENZA PROTEINS
#346Novel Immunogenic Compositions For The Prevention And Treatment of Meningococcal Disease
#347Immunogenic compositions for the prevention and treatment of meningococcal disease
#348Immunogenic compositions for the prevention and treatment of meningococcal disease
#349Prevention and Treatment of Amyloidogenic Disease
#350STABLE IMMUNOGENIC PROTEIN HAVING MULTIPLE CYSTEINES MOLECULES PROCESS THEREFOR AND COMPOSITION THEREOF
#351Process for the production of immunogenic compositions
#352Polyvalent conjugate vaccine for cancer
#353Saponin adjuvant compositions and methods relating thereto
#354Compositions and methods for preventing or treating infection
#355IMMUNIZING COMPOSITION FOR REDUCING STREPTOCOCCAL INFECTIONS
#356VIRUS LIKE PARTICLES COMPRISING TARGET PROTEINS FUSED TO PLANT VIRAL COAT PROTEINS
#357Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
#358THERAPEUTIC COMBINATION
#359Immunogenic compositions for the prevention and treatment of meningococcal disease
#360Multiepitope vaccine for Her2/neu-associated cancers
#361PAPILLOMAVIRUS VACCINE COMPOSITIONS
#362IN VIVO EFFICACY OF NY-ESO-1 PLUS ADJUVANT
#363Process and composition for treatment of canine and human leishmaniasis
#364Adjuvant
#365CHLAMYDIA ANTIGENS AND USES THEREOF
#366RECOMBINANT ECTODOMAIN EXPRESSION OF HERPES SIMPLEX VIRUS GLYCOPROTEINS IN YEAST
#367COMPOSITION
#368IMMUNOGENIC COMPOSITIONS HAVING LOW SODIUM CHLORIDE CONCENTRATION
#369Non-lipidated variants of ORF2086 antigens
#370Recombinant RSV vaccines
#371ADJUVANT COMPOSITIONS COMPRISING A NON-IONIC ISOTONICITY AGENT
#372CASB7439 constructs
#373Recombinant proteins from filoviruses and their use
#374NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS
#375NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS
#376Methods for one-dose intradermal delivery for non-live trivalent influenza vaccine
#377Modified HIV-1 Envelope Proteins
#378NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE
#379Influenza Vaccines, Antigens, Compositions, and Methods
#380KITS FOR ONE-DOSE INTRADERMAL DELIVERY FOR NON-LIVE TRIVALENT INFLUENZA VACCINE
#381NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS
#382Malaria prime/boost vaccines
#383Alpha lactalbumin immunization methods
#384Inactivated dengue virus vaccine with aluminium-free adjuvant
#385Prevention and Treatment of Amyloidogenic Disease
#386Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
#387Vaccines against chlamydial infection
#388HIV-1 Immunogenic Compositions
#389PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES
#390Diagnosis and treatment of infection and Chagas disease
#391Chimeric HIV Antigens
#392IMMUNOSTIMULATING SAPONINS FOR USE IN SITU TUMOR-DESTRUCTION THERAPY
#393Chimeric MSP-based malaria vaccine
#394Vaccines
#395VACCINE COMPOSITIONS
#396Bluetongue virus recombinant vaccines and uses thereof
#397FOOT AND MOUTH DISEASE VIRUS RECOMBINANT VACCINES AND USES THEREOF
#398Compositions and methods
#399Vaccines
#400Vaccine compositions comprising a saponin adjuvant
#401TUBERCULOSIS RV2386C PROTEIN, COMPOSITIONS AND USES THEREOF
#402THERAPEUTIC COMBINATION
#403PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES
#404PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES
#405POLYVALENT, PRIMARY HIV-1 GLYCOPROTEIN DNA VACCINES AND VACCINATION METHODS
#406Vaccine formulations comprising saponin-containing adjuvants
#407Recombinant antigen
#408HETERLOGOUS PRIME-BOOST IMMUNIZATION REGIMEN
#409Influenza B Vaccines
#410Vaccine against varicella zoster virus
#411Inactivated Live-Attenuated Bluetongue Virus Vaccine
#412COMPOSITION COMPRISING ISCOM PARTICLES AND LIVE MICRO-ORGANISMS
#413Immunogenic compositions for the prevention and treatment of meningococcal disease
#414Soluble stabilized trimeric hiv env proteins and uses thereof
#415DOUBLE-LABELLING AGENTS BASED ON VINYL SULPHONE
#416Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
#417PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
#418COMPOSITION FOR THERAPY AND/OR FOR PROPHYLAXIS OF HBV-INFECTIONS AND HBV-MEDIATED DISEASES
#419Vaccine for treatment and prevention of herpes simplex virus infection
#420VACCINE AGAINST VARICELLA ZOSTER VIRUS
#421Adjuvant
#422Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
#423Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis
#424Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
#425Recombinant HCV E2 glycoprotein
#426Vaccine composition and immunization method
#427Immunogenic compositions containing H7 flagella and methods of use thereof
#428VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
#429Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
#430Immunogenic composition
#431Conjugation process for PNAG and a carrier protein
#432Multitype HPV peptide compositions and methods for treatment or prevention of human papillomavirus infection
#433Recombinant RSV antigens
#434Method of eliciting an immune response against pandemic influenza virus
#435METHOD FOR REFOLDING NEISSERIAL NSPA PROTEIN
#436Activation of natural killer (NK) cells and methods of use
#437VACCINE
#438Vaccines for malaria
#439VACCINES FOR MALARIA
#440VACCINES
#441alpha toxin proteins
#442VACCINE
#443NOVEL VACCINE COMPOSITION
#444PROTECTION OF AN ANIMAL AGAINST PESTIVIRUS INFECTION
#445Infectious cDNA of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
#446FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS
#447MAGE3 polypeptides
#448Process for the production of immunogenic compositions
#449Vaccines Containing Non-Live Antigenic Vectors
#450PAPILLOMAVIRUS VACCINE COMPOSITIONS
#451Oil-in-water emulsion influenza vaccine
#452Fusion proteins of mycobacterium tuberculosis
#453Fusion proteins of
#454Microfluidized oil-in-water emulsions and vaccine compositions
#455Vaccines Against Chlamydial Infection
#456THERAPEUTIC COMBINATION
#457METHODS AND COMPOSITIONS FOR VACCINATION OF POULTRY
#458METHODS AND COMPOSITIONS FOR VACCINATION OF POULTRY
#459Use of lipid containing particles comprising Quillaja saponins for the treatment of cancer
#460NOVEL METHOD AND COMPOSITIONS
#461IMMUNOLOGICAL COMPOSITION
#462VACCINE COMPOSITIONS
#463COMBINATION OF TYROSINE KINASE INHIBITOR AND HER-2/NEU FOR CANCER THERAPY
#464Immunogenic complexes and methods relating thereto
#465Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with Surgery, Chemotherapy or Radiotherapy for the Treatment of Cancer
#466Method of elicting or inducing an immune response
#467Adjuvant compositions
#468Compositions and methods for WT1 specific immunotherapy
#469Fusion proteins of
#470THERAPEUTIC COMBINATION
#471PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
#472Malaria prime/boost vaccines
#473NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA
#474PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
#475PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES
#476Vaccine Compositions Comprising Virosomes and a Saponin Adjuvant
#477Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)
#478Modified HIV-1 envelope proteins
#479Reducing interference between oil-containing adjuvants and surfactant-containing antigens
#480VACCINE DELIVERY SYSTEM
#481Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
#482Composition comprising fractions or sub-fraction of leishmania promastigotes or leishmania amastigotes called fucose mannose ligand (fml) and saponin, composition for preparation of leishmaniasis transmission blocking vaccines in humans and animals comprising fractions or sub-fractions of leishmania promastigotes or leis
#483Liposome-mediated ligation
#484COMPOSITION AND METHODS OF MAKING AND USING INFLUENZA PROTEINS
#485Prevention and treatment of amyloidogenic disease
#486Antibody production elicited by a DNA vaccine delivered by electroporation
#487Novel vaccine
#488Immunizing Against HIV Infection
#489Influenza vaccine
#490Recombinant Subunit Vaccine
#491Vaccine for avian influenza and methods of use
#492Method for preventing or treating infection
#493Chimeric MSP-based malaria vaccine
#494ADJUVANTED VACCINE
#495Humanized antibodies that recognize beta amyloid peptide
#496Polyvalent conjugate vaccine for cancer
#497FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS
#498Use of alpha-toxin for treating and preventing staphylococcus infections
#499Glycolipopeptide antibodies
#500VACCINES AGAINST CHLAMYDIAL INFECTION
#501Advanced genetic vaccines
#502Anti-malaria vaccine
#503VACCINES
#504Vaccine For Periodontal Disease
#505Vaccine
#506Prime boost vaccine for the protection of equines against equine influenza
#507HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE
#508Vaccine Compositions Comprising a Saponin Adjuvant
#509HPV antigens, vaccine compositions, and related methods
#510Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
#511Fusion proteins of
#512Vaccines and methods to treat canine influenza
#513Immunomodulating Compositions and Uses Therefor
#514Papillomavirus vaccine compositions
#515Prevention and treatment of amyloidogenic diseases
#516Prevention and treatment of amyloidogenic diseases
#517Fusion proteins of
#518Optimal Polyvalent Vaccine for Cancer
#519PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
#520Prevention and treatment of amyloidogenic disease
#521Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents
#522Adjuvant systems and vaccines
#523Canine combination vaccines
#524Humanized antibodies that recognize beta amyloid peptide
#525Malaria MSP-1 C-terminal enhanced subunit vaccine
#526Sustained release vaccine composition
#527Method for enhancing T cell response
#528NOVEL VACCINE COMPOSITION
#529CANINE VACCINES
#530Vaccine
#531METHODS AND COMPOSITIONS FOR INCREASED PRIMING OF T-CELLS THROUGH CROSS-PRESENTATION OF EXOGENOUS ANTIGENS
#532Immunization Against Chlamydia Infection
#533OIL IN WATER EMULSIONS CONTAINING SAPONINS
#534FORMULATIONS USEFUL FOR IMMUNOTHERAPY FOR CANCERS CONTAINING BACTERIAL COMPONENT AS AN ACTIVE INGREDIENT
#535VACCINES
#536Malaria Prime/Boost Vaccines
#537Use of alpha-toxin for treating and preventing staphylococcus infections
#538Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
#539QS-21 and IL-12 as an adjuvant combination
#540CHLAMYDIA VACCINES
#541Vaccines
#542VACCINE COMPRISING GP120 AND NEF AND/OR TAT FOR THE IMMUNIZATION AGAINST HIV
#543FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS
#544Polynucleotides encoding alpha toxin proteins
#545PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
#546Composition comprising iscom particles and live micro-organisms
#547VACCINES
#548FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS
#549FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS
#550Vaccines
#551Humanized antibodies that recognize beta amyloid peptide
#552Method for Refolding Neisserial Nspa Protein
#553Therapeutic binding agents against MUC-1 antigen and methods for their use
#554Prime-boost vaccine for the protection of equines against viral infection
#555Influenza recombinant subunit vaccine
#556Interleukin-12 as a veterinary vaccine adjuvant
#557Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
#558Moraxella bovis cytotoxin, cytotoxin gene, antibodies and vaccines for prevention and treatment of moraxella bovis infections
#559Methods and compositions for vaccination of poultry
#560Methods and compositions for vaccination of poultry
#561Mage-3 and NY-ESO-1 Based Polyvalent Vaccine for Cancer Immunotherapy
#562Non-live trivalent influenza vaccine for one-dose intradermal delivery
#563Vaccine Compositions Comprising An Interleukin 18 And Saponin Adjuvant System
#564Immunogenic Compositions
#565In vivo efficacy of ny-eso-1 plus adjuvant
#566Fusion proteins of
#567Vaccines
#568Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
#569Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
#570Polypeptides of streptococcus pyogenes
#571Non-toxic mutants of pathogenic gram-negative bacteria
#572Vaccines and methods to treat canine influenza
#573Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
#574STREPTOCOCCUS EQUI COMPOSITIONS AND METHODS OF USE
#575Non-toxic mutants of pathogenic gram-negative bacteria
#576Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
#577Influenza recombinant subunit vaccine
#578Influenza recombinant subunit vaccine
#579Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
#580Vaccine Composition Against Malaria
#581Methods and compositions for inducing antigen-specific immune responses
#582Therapeutic combination
#583Immunogenic compositions for the prevention and treatment of meningococcal disease
#584Formulations and process for production of Bordetella bronchiseptica P68 antigen and vaccines
#585Neisserial vaccine compositions comprising a combination of antigens
#586Quil A fraction with low toxicity and use thereof
#587Gp120 specific antigens and uses thereof
#588Therapeutic combination
#589Prostate specific antigens and uses thereof
#590Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
#591Vaccines
#592Compositions of CpG and saponin adjuvants and uses thereof
#593Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
#594Methods for assessing antibodies to neurodegenerative disease-associated antigens
#595Ganglioside-KLH conjugate vaccine with QS-21
#596Composition for vaccination
#597Immunogenic compositions
#598Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
#599Mutant protein and refolding method
#600Iscom preparation and use thereof